Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis DOI Creative Commons
Xinyu Tong, Lijuan Shen, Xiaomin Zhou

et al.

Drugs in R&D, Journal Year: 2023, Volume and Issue: 23(3), P. 197 - 210

Published: Aug. 9, 2023

At present, the therapies of dilated cardiomyopathy concentrated on symptoms heart failure and related complications. The study is to evaluate clinical efficacy a combination various conventional adjuvant drugs in treating via network meta-analysis. was reported according PRISMA 2020 statement. From inception through 27 June 2022, PubMed, Embase, Cochrane library, Web Science databases were searched for randomized controlled trials medicines cardiomyopathy. quality included studies evaluated risk bias assessment. R4.1.3 Revman5.3 software used analysis. There 52 this study, with total 25 medications sample size 3048 cases. meta-analysis found that carvedilol, verapamil, trimetazidine top three improving left ventricular ejection fraction (LVEF). Ivabradine, bucindolol, verapamil 3 end-diastolic dimension (LVEDD). l-thyroxine, atorvastatin end-systolic (LVESD). Trimetazidine, pentoxifylline, bucindolol New York Heart Association classification (NYHA) cardiac function score. reducing rate (HR). A different therapy may increase effectiveness Beta-blockers, especially can improve remodeling, function, patients (DCM). Hence, they be if tolerate them. If LVEF HR do not meet standard, ivabradine also other treatments. However, since number our research limited, large size, multi-center, high-quality are required corroborate findings.

Language: Английский

La desnutrición en la insuficiencia cardíaca. La importancia de evaluar la congestión y la sarcopenia DOI
Juana Carretero Gómez,

Tomás Francisco Galeano Fernández,

Antonio Sebastián Vidal Ríos

et al.

Revista Clínica Española, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Citations

0
Health‐related quality of life across heart failure categories: associations with clinical characteristics and outcomes DOI Creative Commons
Camilla Settergren,

Lina Benson,

Ulf Dahlström

et al.

ESC Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Abstract Aims The study aims to examine characteristics and outcomes associated with health‐related quality of life (HRQoL) in patients heart failure (HF) preserved, mildly reduced ejection fraction (EF) (HFpEF, HFmrEF HFrEF). Methods results Data on HRQoL were collected the Swedish Heart Failure Registry (SwedeHF; 2000–2021) using EuroQoL 5‐dimensional visual analogue scale (EQ 5D‐vas). Baseline EQ 5D‐vas scores categorized as ‘best’ (76–100), ‘good’ (51–75), ‘bad’ (26–50) ‘worst’ (0–25). Independent associations between patients' 5D‐vas, well assessed. Of 40 809 (median age 74 years; 32% female), 29% ‘best’, 41% ‘good’, 25% 5% categories, similarly distributed across all EF categories. Higher New York Association (NYHA) class was strongly lower regardless followed by chronic obstructive pulmonary disease, smoking, body mass index, higher rate, anaemia, previous stroke, ischaemic use diuretics living alone, whereas income, male sex, outpatient status systolic blood pressure inversely Patients category compared had highest risk all‐cause death [adjusted hazard ratios 1.97, 95% confidence interval (CI) 1.64–2.37 HFrEF, 1.77, CI 1.30–2.40 1.43 1.02–2.00 HFpEF]. Conclusions Most two NYHA strongest association worst at mortality.

Language: Английский

Citations

0
Renal denervation in the setting of heart failure DOI Creative Commons

Franziska Koppe-Schmeißer,

Karl Fengler,

Karl‐Patrik Kresoja

et al.

Heart Failure Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

Abstract Renal Denervation (RDN) has emerged over the last decade as a third pillar in treatment of arterial hypertension, alongside pharmacotherapy and lifestyle modifications. Mechanistically, it reduces central sympathetic overactivation, process also relevant to heart failure. In this mini-review, we summarize development RDN for failure, discuss current evidence supporting its effects, provide an outlook on future developments.

Language: Английский

Citations

0
Cardiac computed tomography-derived coronary artery volume to myocardial mass for the prediction of risk stratification for acute coronary syndrome DOI Creative Commons

Erin Ding,

Liang Chen, Xiaoyu Wei

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Feb. 13, 2025

Purpose The study aimed to assess various characteristics of coronary computed tomography angiography (CCTA) in patients presenting with suspected artery disease (CAD). Additionally, the research sought investigate predictive value volume myocardial mass (V/M) derived from CCTA risk stratification for acute syndrome (ACS) and determine relationship between V/M ratio Global Registry Acute Coronary Events (GRACE) score ACS. Methods This was a single-center, retrospective study. magnitude investigated ACS ( n = 168), stable angina pectoris (SAP) 160), healthy controls 122) among 450 CAD who did not require urgent angiography. Patients underwent 0.5–6 months (median 3.3 months) before SAP event. All invasive (ICA) at time Mantel test used factors influencing CAD. Receiver Operating Characteristic (ROC) curve analysis accuracy predicting Pearson correlation utilized analyze GRACE score, independent predictors high were screened using univariate multivariate logistic regression analysis. Results shows that key left ventricle (M), V/M, CT angiography-derived fractional flow reserve (FFR ) p < 0.01). significantly lower than (21.7 ± 6.96, 31.0 9.90, vs. 43.3 11.50 mm 3 /g; 0.001). Lower ratios found progression unstable (UAP) infarction (AMI) (17.8 5.30, 24.3 6.70, 9.90 ROC outperformed FFR , % DS [AUC: 0.78 [95% CI: 0.74–0.83] 0.74 0.69–0.79], 0.60 0.53–0.64]], combined AUC three increased significantly, reaching 0.80 [95%(CI): 0.76–0.85]. Furthermore, subgroup patients, results negatively correlated be an predictor >140 Conclusions is valuable stratified prediction independently associated score.

Language: Английский

Citations

0
VERICIDuAT: Estudio en vida real de vericiguat en pacientes con insuficiencia cardíaca con fracción de eyección reducida DOI
Sofía Russo Botero,

Miriam Ripoll Martínez,

Lorenzo Fácila

et al.

Revista Clínica Española, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Citations

0
Mechanisms of exercise intolerance in hear-t failure with preserved ejection fraction (HFpEF) DOI Creative Commons

Brandon Pecchia,

Roy Samuel,

Vacha Shah

et al.

Heart Failure Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: March 13, 2025

Language: Английский

Citations

0
Evaluación de las presiones de llenado y la sobrecarga de volumen en la insuficiencia cardiaca: una visión actualizada DOI
Rafael de la Espriella, Marta Cobo Marcos, Enrique Santas

et al.

Revista Española de Cardiología, Journal Year: 2022, Volume and Issue: 76(1), P. 47 - 57

Published: Oct. 14, 2022

Citations

15
Diagnosis and management of Becker muscular dystrophy: the French guidelines DOI
Armelle Magot, Karim Wahbi,

France Leturcq

et al.

Journal of Neurology, Journal Year: 2023, Volume and Issue: 270(10), P. 4763 - 4781

Published: July 9, 2023

Language: Английский

Citations

7
Heart failure with preserved ejection fraction and atrial fibrillation: clinical management in the context of recent therapeutic advances in heart failure and electrophysiology DOI Creative Commons
Eunice Yang, Haroon Rashid

Frontiers in Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Jan. 29, 2024

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Both conditions carry overlapping symptomatology, delineating between AF HFpEF from a diagnostic standpoint is challenging echocardiographic biomarker assessments used to diagnose may be impacted by AF. Indeed, these two are commonly found in the same individual, so much that has been proposed criteria for HFpEF. The frequent concomitant presence of associated poorer quality life, exertional capacity, well increased risk decompensated heart all-cause mortality. Though deleterious effects patients described, we currently only superficial understanding complex interplay conditions. Preliminary studies on intervening very small, mixed data whether modifying natural history can lead improvement (HF) outcomes In this review, will describe clinical implications carrying both cardiovascular conditions, address recent advances AF, highlight preliminary targeted at reduction burden

Language: Английский

Citations

2
Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9 DOI Creative Commons

Lichao Lin,

Huizhen Yu,

Yan Xue

et al.

BMC Medical Genomics, Journal Year: 2024, Volume and Issue: 17(1)

Published: Feb. 21, 2024

Heart failure (HF) is a prevalent clinical syndrome with diverse etiologies. It crucial to identify novel therapeutic targets based on underlying causes. Here, we aimed use proteome-wide Mendelian randomization (MR) analyses the associations between genetically predicted elevated levels of circulating proteins and distinct HF outcomes, along specific

Language: Английский

Citations

2